LORCASERIN HYDROCHLORIDE, ADSORBED ON SILICON DIOXIDE (1:2 W/W)

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H14ClN.8O2Si.ClH
Molecular Weight	712.824
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of LORCASERIN HYDROCHLORIDE, ADSORBED ON SILICON DIOXIDE (1:2 W/W)

Structure Search

SMILES

Cl.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.C[C@H]1CNCCC2=CC=C(Cl)C=C12

InChI

InChIKey=JDJKOSZGEYTQNN-UQDQVLRLSA-N

InChI=1S/C11H14ClN.ClH.8O2Si/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9;;8*1-3-2/h2-3,6,8,13H,4-5,7H2,1H3;1H;;;;;;;;/t8-;;;;;;;;;/m0........./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	O2Si
Molecular Weight	60.0843
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C11H14ClN
Molecular Weight	195.689
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.eisai.com/news/news201464.html

Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2c (5-HT2c) receptor 131 Target ID: CHEMBL225 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022529s003lbl.pdf	Agonist 2752		15.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 206 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf	Curative		Approved 8583	Belviq Approved Use Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m^2 or greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition, (e.g., hypertension, dyslipidemia, type 2 diabetes) Launch Date 2012

C_max

Value	Dose	Analyte	Population
38.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
56.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
69.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
78.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
11.16 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.7 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
39.7 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
50.85 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
83.77 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
85.02 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
611 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
808 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1216 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1318 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
172 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
172.2 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
516.9 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
593.8 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1086.2 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
899.2 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
13 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
12.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27692638/	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
11.38 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.23 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.87 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.28 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.55 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.26 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
30% OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
30% OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	3 mg 1 times / day steady-state, oral dose: 3 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
30% OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
30% OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
30% OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
30% OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORCASERIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:65353	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:65353
ChemicalBook	CB61011744	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB61011744
ZINC	ZINC000006733300	http://zinc15.docking.org/substances/ZINC000006733300

PubMed

Title	Date	PubMed
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.	2014-06	24766397
The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?	2014-04	24515599
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].	2014-03-10	24796150
Nonincretin drugs in later-stage development.	2014-01	25618226
Recent advancements in drug treatment of obesity.	2012-10	23101148

Patents

Sample Use Guides

In Vivo Use Guide

One tablet of 10 mg twice daily

Route of Administration: Oral

In Vitro Use Guide

Lorcaserin was evaluated for its ability to inhibit neurotransmitter uptake into rat brain synaptosomes. Lorcaserin weakly inhibited norepinephrine (EC50 = 2500 nM), serotonin (EC50 = 1400 nM), and dopamine (EC50 = 12,000 nM) uptake.

Substance Class	Chemical Created by `admin` on `Tue Apr 01 17:06:54 GMT 2025` Edited by `admin` on `Tue Apr 01 17:06:54 GMT 2025`
Record UNII	3423KE0K4Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LORCASERIN HYDROCHLORIDE, ADSORBED ON SILICON DIOXIDE (1:2 W/W)

Common Name

English

LORCASERIN HYDROCHLORIDE PREMIX

Preferred Name

English

Code System Code Type Description

PUBCHEM

122706894

Created by admin on Tue Apr 01 17:06:54 GMT 2025 , Edited by admin on Tue Apr 01 17:06:54 GMT 2025

PRIMARY

FDA UNII

3423KE0K4Y

Created by admin on Tue Apr 01 17:06:54 GMT 2025 , Edited by admin on Tue Apr 01 17:06:54 GMT 2025

PRIMARY

Related Record Type Details


					637E494O0Z

LORCASERIN

PARENT -> SALT/SOLVATE